Microbial Colonization and Drug Resistance in Patients with Cystic Fibrosis

Abstract

Background: Cystic fibrosis (CF) is a genetic disease with an autosomal recessive pattern of inheritance. CF caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and characterized by impaired transport of chloride ions across the cell membrane. Staphylococcus aureus, Pseudomonas aeruginosa, and Burkholderia cepacia have been identified in the cultures of respiratory secretions of CF patients, and infections of these microorganisms are associated with high rates of morbidity and mortality. In patients with CF, severe inflammation of the airway can cause advanced bronchiectasis, which may result in respiratory failure and death. Objectives: This study aimed at evaluating the clinical findings of laboratory tests, bacterial colonization, and drug resistance in children and young adults with CF who hospitalized at the

Molecular Identification of Gram-Negative Bacteria in Respiratory Samples of Cystic Fibrosis Patients from a Children Referral Hospital in Tehran

“…Based on the molecular investigation, P. aeruginosa was the most frequent species in the sputum of CF patients in our study. Keating (19). The results of these three studies are comparable to the findings of the current study.…”

New Treatment Approaches of Pseudomonas aeruginosa Infection in Cystic Fibrosis Lung Disease

“…P. aeruginosa is the main cause of chronic airway infection in this complex inherited disease, as confirmed by an interesting study of one of your articles published in this journal (1). This bacterium is also difficult to eradicate (since the chronic infection is established) and the development of resistance to the antibiotic treatment is also frequent.…”

“…Some studies reported that using inhaled drugs for prophylaxis may decrease some complications in these patients (1,4). In our recent published review, we reported some data about the use of anti-pseudomonal inhaled antibiotics in the eradication of early and chronic infection, to treat acute exacerbations or for prophylaxis.…”